Published in J Pathol on December 10, 2010
MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS One (2014) 1.08
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC Cancer (2011) 1.02
Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases. Skeletal Radiol (2013) 0.93
Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. Neuro Oncol (2013) 0.92
Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res (2011) 0.92
Erlotinib inhibits growth of a patient-derived chordoma xenograft. PLoS One (2013) 0.90
Novel targeted therapies in chordoma: an update. Ther Clin Risk Manag (2015) 0.81
Current therapeutic options and novel molecular markers in skull base chordomas. Neurosurg Rev (2011) 0.80
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol (2016) 0.80
Sustained response of a clivus chordoma to erlotinib after imatinib failure. Case Rep Oncol (2015) 0.79
The molecular aspects of chordoma. Neurosurg Rev (2015) 0.79
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. Neuro Oncol (2014) 0.78
Common somatic alterations identified in maffucci syndrome by molecular karyotyping. Mol Syndromol (2014) 0.78
Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma. Neurosurg Rev (2014) 0.76
Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers. J Pathol (2011) 0.76
Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. Neoplasia (2013) 0.76
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR. Front Oncol (2016) 0.75
Chordoma: The Quest for Better Treatment Options. Oncol Ther (2016) 0.75
Recent advances in understanding and managing chordomas. F1000Res (2016) 0.75
HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. Sci Rep (2017) 0.75
Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets. Surg Neurol Int (2013) 0.75
Paediatric Chordomas. Orphanet J Rare Dis (2015) 0.75
[Novel molecular aspects of chordomas]. Pathologe (2014) 0.75
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med (2011) 8.26
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 5.73
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol (2002) 3.77
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet (2004) 3.38
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol (2004) 3.08
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet (2011) 2.74
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet (2011) 2.62
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet (2013) 2.53
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology (2006) 2.50
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Prosthetic joint infection following total hip replacement: results of one-stage versus two-stage exchange. Int Orthop (2014) 2.16
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol (2002) 2.10
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol (2012) 2.02
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer (2005) 2.01
Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology (2005) 2.00
Failure modes for total ankle arthroplasty: a statistical analysis of the Norwegian Arthroplasty Register. Arch Orthop Trauma Surg (2014) 2.00
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol (2009) 1.96
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol (2012) 1.95
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol (2010) 1.91
Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol (2003) 1.85
Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol (2006) 1.83
NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol (2005) 1.82
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Lymphatics and bone. Hum Pathol (2007) 1.76
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol (2005) 1.72
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol (2008) 1.67
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol (2002) 1.65
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer (2010) 1.63
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol (2009) 1.63
Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res (2011) 1.60
Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer (2011) 1.59
A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer (2010) 1.56
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist (2011) 1.54
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
Survival analysis of 254 patients after manifestation of spinal metastases: evaluation of seven preoperative scoring systems. Spine (Phila Pa 1976) (2011) 1.53
A molecular map of mesenchymal tumors. Genome Biol (2005) 1.52
Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Mod Pathol (2009) 1.51
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
The role of platelets in the treatment of Achilles tendon injuries. J Orthop Res (2012) 1.50
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Revision surgery after total joint arthroplasty: a complication-based analysis using worldwide arthroplasty registers. J Arthroplasty (2013) 1.48
GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol (2009) 1.46
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
The correlation of wear with histological features after failed hip resurfacing arthroplasty. J Bone Joint Surg Am (2013) 1.45
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet (2013) 1.45
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer (2011) 1.44
Ocular adnexal mucosa-associated lymphoid tissue lymphoma in Northern China: high frequency of numerical chromosomal changes and no evidence of an association with Chlamydia psittaci. Leuk Lymphoma (2010) 1.43
Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®. Clin Orthop Relat Res (2014) 1.42